Loading...
XASXBXN
Market cap30mUSD
Jan 08, Last price  
0.02AUD
1D
0.00%
1Q
84.62%
Name

Bioxyne Ltd

Chart & Performance

D1W1MN
XASX:BXN chart
P/E
—
P/S
5.27
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.70%
Rev. gr., 5y
33.46%
Revenues
9m
+80.70%
1,388,8121,684,644837,092674,5631,147,695751,897939,644123,275880,4972,391,7301,645,2382,024,2172,054,2912,151,3752,202,2822,259,2642,110,377463,6365,160,5389,325,020
Net income
-13m
L+586.87%
-3,933,058-1,877,981-1,726,025-1,331,146-210,90680,1441,054-1,784,131-6,191,1131,190,827201,039223,846-765,752-1,311,840-1,265,882-593,095-495,725-494,022-1,939,970-13,325,050
CFO
-4m
L+323.16%
00000000-971,704606,757-166,772348,852-424,048-1,855,355-1,390,36248,24953,134-506,811-841,284-3,559,954
Earnings
Feb 26, 2025

Profile

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
URL
http://www.bioxyne.com/
IPO date
Dec 14, 2000
Employees
16
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
9,325
80.70%
5,161
1,013.06%
464
-78.03%
Cost of revenue
11,321
7,141
1,097
Unusual Expense (Income)
NOPBT
(1,996)
(1,980)
(634)
NOPBT Margin
Operating Taxes
(311)
(74)
(3)
Tax Rate
NOPAT
(1,685)
(1,906)
(634)
Net income
(13,325)
586.87%
(1,940)
292.69%
(494)
-0.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,350
582
BB yield
-13.99%
-2.17%
Debt
Debt current
183
397
Long-term debt
1,164
Deferred revenue
Other long-term liabilities
Net debt
319
(3,846)
331
Cash flow
Cash from operating activities
(3,560)
(841)
(507)
CAPEX
(178)
(57)
(60)
Cash from investing activities
(493)
3,964
27
Cash from financing activities
1,210
947
493
FCF
(4,191)
(2,037)
(305)
Balance
Cash
1,028
3,846
66
Long term investments
Excess cash
562
3,588
43
Stockholders' equity
3,300
15,006
(312)
Invested Capital
3,412
11,977
345
ROIC
ROCE
EV
Common stock shares outstanding
1,930,248
1,344,132
732,432
Price
0.01
-75.00%
0.02
66.67%
0.01
-57.14%
Market cap
9,651
-64.10%
26,883
205.86%
8,789
-50.96%
EV
9,664
22,906
9,174
EBITDA
(1,996)
(1,870)
(603)
EV/EBITDA
Interest
582
582
Interest/NOPBT